Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

被引：141

作者：

Micek, Scott T. ^{[1
]}

机构：

[1] Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2007年 / 45卷

关键词：

D O I：

10.1086/519471

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillin-resistant Staphylococcus aureus ( MRSA). However, as a result of limited tissue distribution, as well as the emergence of isolates with reduced susceptibility and in vitro resistance to vancomycin, the need for alternative therapies that target MRSA has become apparent. New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/ dalfopristin. Additionally, a number of new anti- MRSA compounds are in development, including novel glycopeptides ( dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clinical issues surrounding the newly marketed and investigational agents with activity against MRSA.

引用

页码：S184 / S190

页数：7

共 44 条

[1] Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit [J].

Albanèse, J ;

Léone, M ;

Bruguerolle, B ;

Ayem, ML ;

Lacarelle, B ;

Martin, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) :1356-1358

[2] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[3]

*ARP, INTR ICL

[4] Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska [J].

Baggett, HC ;

Hennessy, TW ;

Rudolph, K ;

Bruden, D ;

Reasonover, A ;

Parkinson, A ;

Sparks, R ;

Donlan, RM ;

Martinez, P ;

Mongkolrattanothai, K ;

Butler, JC .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) :1565-1573

[5]

*BAS PHARM, BAS REP EXC PIV DAT

[6] Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia [J].

Bhavnani, SM ;

Passarell, JA ;

Owen, JS ;

Loutit, JS ;

Porter, SB ;

Ambrose, PG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :994-1000

[7] Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin [J].

Bogdanovich, T ;

Ednie, LM ;

Shapiro, S ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) :4210-4219

[8] Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam [J].

Breedt, J ;

Teras, J ;

Gardovskis, J ;

Maritz, FJ ;

Vaasna, T ;

Ross, DP ;

Gioud-Paquet, M ;

Dartois, N ;

Ellis-Grosse, EJ ;

Loh, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4658-4666

[9]

*CER, CEFT AC

[10] Ceftobiprole: in-vivo profile of a bactericidal cephalosporin [J].

Chambers, HF .

CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 :17-22

← 1 2 3 4 5 →